Business
SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update
TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development
About this update from Scisparc Ltd.
[{"type":"text","content":"TEL AVIV, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (the “SEC”). Recent Corporate Highlights: Issued U.S. patent surrounding the Company’s core technology that treats central nervous systems disordersRecruited first patient in the Phase IIa clinical trial of SCI-110 in Alzheimer's diseaseAdvanced the Phase IIb clinical trial of SCI-110 in patients with Tourette syndromeEntered into a collaboration agreement with ClearMind Medicine Inc. for the development of innovative psychedelic-based pharmaceuticalsEntered into a JV agreement with MitoCare X targeting the discovery of potential drugs for cancers and infectious diseases Oz Adler, SciSparc's Chief Executive Officer, commented, \"2021 was a turnaround year for SciSparc. We successfully up-listed to the Nasdaq stock exchange and raised approximately $8 million from high quality investors. Operationally, we expanded our IP protection in key territories and advanced our programs in Tourette syndrome, Alzheimer's disease and Agitation, Status Epilepticus and pain. In 2022, we plan on continuing our advancement in our clinical and pre- clinical programs and move closer towards developing and presenting innovative therapies.” The annual report, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC website at http://www.sec.gov as well as via the Company’s website at https://investor.scisparc.com. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to the Company’s investor relations contact: [email protected]. About SciSparc (NASDAQ: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development...